Recursion Pharmaceuticals Rises as Positive Phase 1b/2 Trial Results for REC-4881 Validate AI-Driven Drug Discovery Platform [Yahoo! Finance]
Recursion Pharmaceuticals, Inc. - Class A (RXRX)
Company Research
Source: Yahoo! Finance
positive Phase 1b/2 results for REC-4881, which is its investigational allosteric MEK1/2 inhibitor designed to treat Familial Adenomatous Polyposis/FAP. FAP is a rare, life-altering hereditary condition affecting over 50,000 people in the US and EU5. It is driven by inactivating mutations in the APC gene, which typically result in a near-100% lifetime risk of colorectal cancer. Currently, no medical therapies are approved, forcing patients to undergo frequent endoscopic removals and major surgeries, such as colectomies, starting in their early 20s. The TUPELO trial data demonstrated that REC-4881 achieved both rapid and durable clinical activity. The study revealed that 87% of untreated individuals experience a progressive increase in polyp burden, with only 3% showing any modest decrease. The safety profile of REC-4881 remained consistent with the MEK1/2 inhibitor class; most treatment-related adverse events were mild (Grade 1 or 2), such as acneiform dermatitis or elevated blood
Show less
Read more
Impact Snapshot
Event Time:
RXRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RXRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RXRX alerts
High impacting Recursion Pharmaceuticals, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
RXRX
News
- JPMorgan Boosts Rating on Recursion Pharmaceuticals (RXRX) Amid AI-Driven Drug Pipeline [Yahoo! Finance]Yahoo! Finance
- Forget Recursion Pharmaceuticals Stock. This Is a Much Better Buy. [Yahoo! Finance]Yahoo! Finance
- Cathie Wood's ARK Investment Buys 755K Shares Of Recursion Pharmaceuticals, Inc. (RXRX) [Yahoo! Finance]Yahoo! Finance
- Recursion Pharmaceuticals Reports Positive Phase 1b/2 TUPELO Trial Results, Validating AI-Driven Therapy for FAP [Yahoo! Finance]Yahoo! Finance
- Cathie Wood Is Doubling Down on Recursion Pharmaceuticals Stock. Should You Buy RXRX Here? [Yahoo! Finance]Yahoo! Finance
RXRX
Earnings
- 11/5/25 - Beat
RXRX
Sec Filings
- 12/30/25 - Form 4
- 12/29/25 - Form 4
- 12/29/25 - Form 144
- RXRX's page on the SEC website